Screener
Taysha Gene Therapies, Inc. TSHA Issuance of warrants
Issuance of warrants at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued.
The source filing: Taysha Gene Therapies, Inc.’s 10-K, filed March 19, 2026.
- Filed
- Mar 19, 2026, 8:31 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001193125-26-115202
| Line item | For the Year Ended December 31, 2025 | For the Year Ended December 31, 2024 |
|---|---|---|
| Cash paid for interest | $5,399 | $5,282 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Proceeds allocated to Success Fee liability | 217 | — |
| Right-of-use assets obtained in exchange for lease liabilities | 2,374 | — |
| Purchase of research and development license not yet paid | 3,000 | — |
| Non-cash impact of exercise of liability classified warrants | 1,637 | — |
| Property, plant and equipment in accounts payable and accrued expenses | 41 | 346 |
| Offering costs not yet paid | — | 46 |
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is Taysha Gene Therapies, Inc.'s issuance of warrants?
- Taysha Gene Therapies, Inc. (TSHA) reported issuance of warrants of $409.25K in Q4 2025.
- What does issuance of warrants mean?
- Represents the accounting adjustments made to equity accounts resulting from the issuance of warrants. This metric reflects the dilution impact and the non-cash financing component associated with equity-linked instruments. It is a key indicator of how the company manages its capital structure and potential future share dilution.
Ask your AI about Taysha Gene Therapies, Inc.'s issuance of warrants.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude